Clinical Trial

IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer

Study acronym: IMPACT-C
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-01-12; most recent amendment 2025-10-29.
Status change: Not Yet Recruiting → Recruiting 2025-02-26
Trial Details
NCT Number NCT06206941
Lead Sponsor State University of New York at Buffalo
Collaborators: Thomas Jefferson University, Oregon Health and Science University
Conditions Cancer
Enrollment 450 participants
Start Date 2025-01-02
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-31